TABLE 2.
Medical conditions of the case and control groups
| Variable | Case group (n = 41)a | Control group (n = 82)a | P value |
|---|---|---|---|
| Duration of | |||
| Hospitalization | 100.2 ± 80.01 | 53.82 ± 33.70 | 0.001 |
| Hospitalization before the tigecycline use | 33.66 ± 34.27 | 21.71 ± 18.56 | 0.042 |
| Tigecycline usage | 20.80 ± 16.11 | 17.11 ± 11.59 | 0.195 |
| Hospital exposure | |||
| ICU stayb | 18 (43.9) | 21 (25.6) | 0.040 |
| Surgical proceduresc | 25 (61.0) | 50 (61.0) | 1.000 |
| Intervention proceduresd | 17 (41.5) | 41 (51.2) | 0.307 |
| Indwelling catheter or drainage | |||
| Foley catheter | 24 (58.5) | 31 (39.0) | 0.041 |
| Percutaneous drainage | 22 (53.7) | 50 (61.0) | 0.437 |
| Suction drainage systeme | 12 (29.3) | 4 (4.9) | 0.001 |
| Levin tube | 18 (43.9) | 25 (30.5) | 0.141 |
| Combined antibiotic therapy | 7 (17.1) | 17 (20.7) | 0.629 |
| Exposures to antimicrobial agents | |||
| Narrow-, expanded-, and broad-spectrum cephalosporins | 7 (17.1) | 34 (41.5) | 0.007 |
| Ampicillin-sulbactam and penicillin | 2 (4.9) | 11 (13.4) | 0.147 |
| Glycopeptides and linezolid | 19 (46.3) | 40 (48.9) | 0.799 |
| Metronidazole | 11 (26.9) | 15 (18.3) | 0.274 |
| Antipseudomonal antibioticsf | 33 (80.5) | 58 (70.7) | 0.245 |
a
Data are presented as means ± SD or number (%) of patients.
b
ICU stay at the start of tigecycline therapy.
c
Any surgical procedure under general anesthesia within 30 days prior to the administration of tigecycline.
d
Any intervention procedure except upper or lower GI endoscopy within 30 days prior to the administration of tigecycline.
e
Hemovac, sump, or vacuum dressing at infected site.
f
These include cefepime, piperacillin-tazobactam, carbapenems except ertapenem, colistin, quinolone, and aminoglycoside.